Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pricing Pressures Lower Profits For Chinese Drug Chain Nepstar, While Healthcare Reform Has Opposite Effect On Hospital Chain Chindex - China Earnings Roundup (Part 1)

This article was originally published in PharmAsia News

Executive Summary

Year-end and Q4 earnings results for Chinese healthcare operators and drug stores are shaped by a challenging environment imposed by China's healthcare reform and increasing drug pricing pressure. In 2010, a rising tide of inflation also increased minimum wages and labor costs across the country and impacted companies' bottom lines. Many firms have resorted to business diversification, innovation and enriched pipelines to sustain a strong growth.

Related Content

Shanghai Fosun And Chindex CEO Team Up To Capitalize On China’s Growing Private Markets
China Nepstar Chain Drug Store Eyes Quality As Quantities Grow Rapidly
China’s Private Hospital Market Takes Flight
Hospira Hinges Emerging Market Success On Scale And Differentiation
Hospira Hinges Emerging Market Success On Scale And Differentiation
3SBio To Capitalize On Global Biologics Boom, SciClone Delays Key Financial Filing - Chinese Earnings Roundup (Part 2 of 2)
China Signals Need For Private Investment To Support Its Healthcare Reforms; Private Insurance Options Likely To Widen
In Major Policy Turnaround, Chinese Premier's Office Lifts Restrictions On Foreign Investment In Hospitals
Squeezed by Price Caps And Rising Costs, China's Nepstar Drugstore Chain Pushes Its Own Brands
Riding High And Scaling Up, Chindex Readies Business Model Rollout In China



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts